Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Overview of Relapsed/Refractory DLBCL and Management Strategies

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

Obe-Cel Demonstrates Durable, Safe Responses in Relapsed/Refractory B-ALL

June 18th 2023

Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

June 16th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma

June 15th 2023

Treatment with duvelisib led to a high response rate in patients with peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma.

Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients

June 15th 2023

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

Risk Stratification of Myelodysplastic Syndromes [MDS]

June 15th 2023

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Dr Roloff on the Real-World Outcomes of Brexu-Cel in Relapsed/Refractory B-ALL

June 14th 2023

Gregory W. Roloff, MD, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva

June 14th 2023

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML on Hold After Serious Grade 5 AE

June 14th 2023

The phase 1 PLAT-08 trial investigating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia has been paused following the report of a grade 5 serious adverse effect.

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

June 14th 2023

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

El Rol de Los Tripletes en el Tratamiento de la Leucemia Aguda Mieloblástica

June 13th 2023

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Brentuximab Vedotin Plus Nivolumab/Chemo Elicits 98% ORR in Early-Stage Classical Hodgkin Lymphoma

June 13th 2023

Frontline treatment with the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine led to an overall response rate of 98% and a complete response rate of 93% in patients with early-stage, classical Hodgkin lymphoma.

Zilurgisertib With or Without Ruxolitinib Shows Early Tolerability, Activity in Anemic Myelofibrosis

June 12th 2023

Administration of the selective ALK-2 inhibitor zilurgisertib alone or in combination with ruxolitinib was safe, well tolerated, and showed preliminary signals of clinical activity in patients with primary or secondary myelofibrosis and disease-related anemia.

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

MASP-3 Inhibitor Demonstrates Clinical Efficacy in Paroxysmal Nocturnal Hemoglobinuria

June 11th 2023

OMS906, a MASP-3 inhibitor, normalized hemoglobin, lactate dehydrogenase, and reticulocytes levels in patients with paroxysmal nocturnal hemoglobinuria.

Gilteritinib Shows RFS Benefit as Maintenance, Posttransplant Therapy in MRD+ FLT3-Mutant AML

June 11th 2023

Gilteritinib led to a 48% reduction in disease recurrence for patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease pre and post hematopoietic stem cell transplant compared with placebo, highlighting a role for treatment in this subgroup of patients.

BMS-986158 Plus Rituximab Reduces Spleen Volume, Shows Tolerability in Myelofibrosis

June 11th 2023

The BET inhibitor BMS-986158 combined with ruxolitinib led to robust spleen volume reduction with acceptable tolerability in patients with myelofibrosis. When the BET inhibitor was combined with fedratinib, the safety profile was also determined to be manageable.

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11th 2023

The novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who did not respond or relapsed after at least 1 prior therapy.

Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML

June 11th 2023

Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.